GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hualan Biological Vaccine 301207.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

15.40

-0.13%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.20bn

FY2017FY2025

Net income

CN¥182.9m

FY2017FY2025

Free cash flow

CN¥347.4m

FY2017FY2025

Shareholders' equity

CN¥5.70bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥1.20bnCN¥1.13bnCN¥2.41bnCN¥1.83bnCN¥1.83bnCN¥2.43bnCN¥1.05bnCN¥802.7mCN¥284.9m
Research and developmentCN¥151.3mCN¥162.6mCN¥91.1mCN¥134.6mCN¥144.1mCN¥110.9mCN¥73.0mCN¥53.0mCN¥64.0m
Operating incomeCN¥187.6mCN¥214.9mCN¥1.01bnCN¥592.6mCN¥707.0mCN¥1.07bnCN¥432.0mCN¥299.8m−CN¥100.5m
Net incomeCN¥182.9mCN¥205.5mCN¥860.0mCN¥519.6mCN¥621.0mCN¥924.9mCN¥375.3mCN¥270.1m−CN¥76.9m
Diluted earnings per share0.310.351.410.861.151.710.630.45-0.13

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥6.84bnCN¥7.52bnCN¥8.00bnCN¥7.08bnCN¥4.52bnCN¥3.65bnCN¥1.79bnCN¥1.37bnCN¥845.7m
Cash and short-term investments—CN¥2.08bnCN¥2.61bnCN¥2.02bnCN¥957.4mCN¥865.2mCN¥500.6mCN¥143.0mCN¥26.6m
Total liabilitiesCN¥1.14bnCN¥1.51bnCN¥1.73bnCN¥1.58bnCN¥1.72bnCN¥1.46bnCN¥531.9mCN¥481.2mCN¥228.9m
Debt—CN¥300.2mCN¥300.2mCN¥300.2mCN¥502.3mCN¥200.0m———
Shareholders' equityCN¥5.70bnCN¥6.01bnCN¥6.26bnCN¥5.50bnCN¥2.81bnCN¥2.19bnCN¥1.26bnCN¥886.9mCN¥616.8m
Shares outstanding596m595m610m602m540m541m596m596m596m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operationsCN¥357.1mCN¥468.0mCN¥888.0mCN¥288.7mCN¥569.3mCN¥693.7mCN¥275.0mCN¥94.5mCN¥22.2m
Capital spending−CN¥9.7m−CN¥51.6m−CN¥62.6m−CN¥92.6m−CN¥636.1m−CN¥532.3m−CN¥143.9m−CN¥62.8m−CN¥25.6m
Free cash flowCN¥347.4mCN¥416.4mCN¥825.4mCN¥196.0m−CN¥66.7mCN¥161.4mCN¥131.1mCN¥31.7m−CN¥3.4m
Dividends paid−CN¥507.9m−CN¥334.3m−CN¥126.1m−CN¥90.9m−CN¥12.8m−CN¥4.6m——−CN¥100.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥17.6mCN¥26.8mCN¥396.5mCN¥746.0mCN¥35.7mCN¥24.3mCN¥170.4mCN¥921.8m
Operating income−CN¥47.1m−CN¥20.4mCN¥134.0mCN¥127.2m−CN¥24.3mCN¥36.5m−CN¥90.7mCN¥281.3m
Net income−CN¥922,550CN¥37.4mCN¥50.6mCN¥111.5m−CN¥12.0mCN¥32.8m−CN¥61.8mCN¥242.1m
Diluted earnings per share-0.000.060.080.19-0.020.05-0.100.41
Cash from operations———CN¥116.0mCN¥108.0m−CN¥2.0m—CN¥110.0m
Capital spending−CN¥4.0m−CN¥2.0m−CN¥5.0m—−CN¥2.0m−CN¥2.0m−CN¥13.0m−CN¥9.0m
Free cash flow————CN¥106.0m−CN¥4.0m—CN¥101.0m
Total assetsCN¥6.28bnCN¥6.84bnCN¥6.84bnCN¥7.18bnCN¥6.91bnCN¥7.44bnCN¥7.52bnCN¥7.64bn
Cash and short-term investments———CN¥2.39bnCN¥2.02bnCN¥2.20bnCN¥2.08bnCN¥1.88bn
Debt———CN¥20.5mCN¥12.0mCN¥300.0mCN¥300.2mCN¥300.0m
Shareholders' equityCN¥5.26bnCN¥5.74bnCN¥5.70bnCN¥5.67bnCN¥5.92bnCN¥6.05bnCN¥6.01bnCN¥6.09bn

Financial ratios

Data as of 3 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin15.6%19.1%41.9%32.5%38.6%44.3%
Net margin15.2%18.2%35.7%28.5%33.9%38.1%
Return on equity3.2%3.4%13.7%9.5%22.1%42.3%
Return on assets2.7%2.7%10.8%7.3%13.7%25.4%
Free cash flow yield3.1%4.3%7.8%3.2%11.1%11.3%
Revenue growth6.6%-53.2%32.0%-0.2%-24.6%131.3%
Earnings growth-11.0%-76.1%65.5%-16.3%-32.9%146.4%
Current ratio3.92x3.40x3.10x2.73x1.51x1.69x
Debt to equity—0.05x0.05x0.05x0.18x0.09x
Equity ratio83.3%79.9%78.3%77.7%62.1%60.0%
Interest coverage73.57x34.59x163.25x54.76x52.33x482.11x
R&D as a share of sales12.6%14.4%3.8%7.4%7.9%4.6%
Buybacks as a share of market value-0.2%2.4%-1.3%-11.4%0.1%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-13.0%-13.1%—
Operating income-31.8%-29.5%—
Net income-29.4%-27.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings60.750.719.734.4
Price to sales9.29.27.09.8

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 27 Oct 2025.

FY2025FY2024FY2023FY2022
Paid in the year0.800.600.300.133
  • 3-for-2 split · 7 Jun 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.